HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: the first case report in Thailand.

Abstract
Radioimmunotherapy (RIT) with 131-rituximab is a safe and effective treatment in patients with relapsed, refractory follicular lymphoma. The authors demonstrated the first case of 131-rituximab treatment in the patient with relapsed non-Hodgkin's lymphoma (NHL) in Thailand. There was no immediate complication after treatment. Impressive treatment response occurred.
AuthorsArpakorn Kositwattanarerk, Wirote Changmuang, Jatupol Sangsuriyan, Kittiphong Thongklam, Chanika Sritara, Chirawat Utamakul, Wichana Chamroonrat, Kanungnij Thamnirat, Yoch Anongpornyochkul, Suporn Chancharunee
JournalJournal of the Medical Association of Thailand = Chotmaihet thangphaet (J Med Assoc Thai) Vol. 96 Issue 6 Pg. 756-60 (Jun 2013) ISSN: 0125-2208 [Print] Thailand
PMID23951835 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • 131I-rituximab
Topics
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Female
  • Humans
  • Lymphoma, Non-Hodgkin (diagnosis, radiotherapy)
  • Radioimmunotherapy
  • Recurrence
  • Rituximab
  • Thailand

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: